[2-[(1S,2S,4S,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [2-[(1S,2S,4S,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
• 化学式: C₃₂H₄₄O₇
• 分子量: 540.7
• InChiKey: LUKZNWIVRBCLON-BACZTASJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  99.1
• 氢给体数：
  1
• 氢受体数：
  7

ADMET

毒理性

• 在妊娠和哺乳期间的影响

哺乳期使用总结：尽管没有进行测量，吸入型皮质类固醇被母体吸收进入血液和分泌到母乳中的量可能太小，不足以影响哺乳的婴儿。专家意见认为，吸入、鼻腔和口服皮质类固醇在哺乳期间使用是可以接受的。 ◉ 对哺乳婴儿的影响：没有报告任何皮质类固醇有影响。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Although not measured, the amounts of inhaled corticosteroids absorbed into the maternal bloodstream and excreted into breastmilk are probably too small to affect a breastfed infant. Expert opinion considers inhaled, nasal and oral corticosteroids acceptable to use during breastfeeding. ◉ Effects in Breastfed Infants:None reported with any corticosteroid. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• Active agent delivery systems and methods for protecting and administering active agents
  申请人：New River Pharmaceuticals Inc.

  公开号：US20040063628A1

  公开（公告）日：2004-04-01

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽的组成部分，与活性物质共价连接的组合物和用于给予共轭活性物质组合物的方法。
• Crystalline Ciclesonide Methanol Solvate Form C
  申请人：Cipla Limited

  公开号：EP2392584A1

  公开（公告）日：2011-12-07

  The present invention relates to crystalline ciclesonide methanol solvate Form C, processes for its preparation, its use in the synthesis of crystalline ciclesonide Form A and its use in medicine.

  本发明涉及结晶环索地酮甲醇溶剂 Form C，其制备方法，其在合成结晶环索地酮 Form A 中的应用以及其在医学上的应用。
• PROCESSES FOR THE PREPARATION OF CICLESONIDE AND ITS CRYSTAL MODIFICATION
  申请人：Phull Manjinder Singh

  公开号：US20100222572A1

  公开（公告）日：2010-09-02

  Improved processes for the synthesis of ciclesonide, chemically termed as [11β,16α(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione and its crystal modification.

  改进的合成环索尼德的过程，化学术语为[11β,16α(R)]-16,17-[(环己基亚甲基)双（氧基）]-11-羟基-21-(2-甲基-1-氧代丙氧基)孕-1,4-二烯-3,20-二酮及其晶体修饰。
• Inhaled Combination Therapy
  申请人：Pulmagen Therapeutics (Synergy) Limited

  公开号：US20130203716A1

  公开（公告）日：2013-08-08

  There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

  提供了一种利用甲基黄嘌呤衍生物，如茶碱和类固醇的协同组合治疗慢性阻塞性肺疾病的方法，其中该组合物通过吸入途径用于肺递送。
• Active agent delivery sytems and methods for protecting and administering active agents
  申请人：Shire LLC

  公开号：EP2266590A2

  公开（公告）日：2010-12-29

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂给药系统，更具体地说，涉及由与活性剂共价连接的氨基酸（作为单个氨基酸或肽）组成的组合物以及给药共轭活性剂组合物的方法。